Literature DB >> 16151756

[Therapy for organic erectile dysfunction].

A J Becker1, M Mayer, C G Stief.   

Abstract

Erectile dysfunction is a common disease of men. It is associated with various comorbidities and has a prevalence of about 50% in the 7th decade. Erectile dysfunction often affects the quality of life of the patient and his partner, and it is very important to offer adequate therapy that respects the individual circumstances of each patient. The mandatory diagnostic work-up includes a medical and psychosexual history, a physical examination and routine laboratory tests. Besides psychotherapy, oral pharmacotherapy with oral PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) is the most effective therapy for erectile dysfunction and is superior to centrally acting drugs (yohimbine). In cases of failure or contraindication of oral pharmacotherapy, local pharmacotherapy is the second-line therapy. The third-line options are vacuum erectile devices and penile implants, and these have a high patient satisfaction. New therapeutic strategies such as anti-serotoninergic substrates and growth hormone offer a promising future for the therapy of erectile dysfunction but remain to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16151756     DOI: 10.1007/s00120-005-0910-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  32 in total

1.  Oxytocinergic and serotonergic innervation of identified lumbosacral nuclei controlling penile erection in the male rat.

Authors:  Y Tang; O Rampin; A Calas; P Facchinetti; F Giuliano
Journal:  Neuroscience       Date:  1998-01       Impact factor: 3.590

2.  Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil.

Authors:  Chris McMahon
Journal:  J Sex Med       Date:  2004-11       Impact factor: 3.802

3.  Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat.

Authors:  H Mizusawa; P Hedlund; J D Brioni; J P Sullivan; K-E Andersson
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

4.  Modification of sexual behavior of Long-Evans male rats by drugs acting on the 5-HT1A receptor.

Authors:  J Rehman; A Kaynan; G Christ; M Valcic; S Maayani; A Melman
Journal:  Brain Res       Date:  1999-03-13       Impact factor: 3.252

5.  Sildenafil, a novel effective oral therapy for male erectile dysfunction.

Authors:  M Boolell; S Gepi-Attee; J C Gingell; M J Allen
Journal:  Br J Urol       Date:  1996-08

6.  Differential influence of a selective melanocortin MC4 receptor antagonist (HS014) on melanocortin-induced behavioral effects in rats.

Authors:  A V Vergoni; A Bertolini; F Mutulis; J E Wikberg; H B Schiöth
Journal:  Eur J Pharmacol       Date:  1998-12-04       Impact factor: 4.432

7.  The cloning of a family of genes that encode the melanocortin receptors.

Authors:  K G Mountjoy; L S Robbins; M T Mortrud; R D Cone
Journal:  Science       Date:  1992-08-28       Impact factor: 47.728

8.  Growth hormone enhances regeneration of nitric oxide synthase-containing penile nerves after cavernous nerve neurotomy in rats.

Authors:  G W Jung; E M Spencer; T F Lue
Journal:  J Urol       Date:  1998-11       Impact factor: 7.450

9.  [Treatment of erectile dysfunction with vacuum pumps].

Authors:  H Derouet; U Zehl
Journal:  Urologe A       Date:  1993-07       Impact factor: 0.639

Review 10.  [Sex, erectile dysfunction, and the heart: a growing problem].

Authors:  Günter Görge; Stephan Flüchter; Michael Kirstein; Thomas Kunz
Journal:  Herz       Date:  2003-06       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.